SLS - NASDAQ
SELLAS Life Sciences Group, Inc.
$8.19
-1.7%SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
At a Glance
Live SnapshotSELLAS Life Sciences Group, Inc. Profit Bridge
Profitability Analysis
SELLAS Life Sciences Group, Inc. Income Statement
SLS • NASDAQ
| SELLAS Life Sciences Group, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
0.0 | 0.0 | 0.0 | 1M | 7.6M | 1.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.3M | 2.5M | 2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (100K) | (200K) | (0.0) | (0.0) | (0.0) | (0.0) | (3K) | (355K) | (1.4M) | (520K) | (49K) | (163K) | (0.0) | (0.0) | (0.0) | (11.4M) | (0.0) | |
0.0 | 0.0 | 0.0 | 900K | 7.4M | 1.9M | 0.0 | 0.0 | 0.0 | -3K | -355K | 7.9M | 2M | -49K | -20.8M | 0.0 | 0.0 | 0.0 | -11.4M | 0.0 | |
OPERATING INCOME | ||||||||||||||||||||
(28.3M) | (31.5M) | (37.9M) | (42.9M) | (32.7M) | (18.9M) | (17.2M) | (31.6M) | (21.2M) | (31.9M) | (33.9M) | (60.1M) | (35.8M) | (21.2M) | (20.8M) | (16.5M) | (17.5M) | (14.6M) | (11.4M) | (2.4M) | |
(12.3M) | (12.4M) | (13.9M) | (12.6M) | (11.3M) | (9.6M) | (9.9M) | (12.8M) | (15.1M) | (12M) | (10.3M) | (31.3M) | (14.6M) | (6.6M) | (9.2M) | (8.8M) | (8.6M) | (4.9M) | (4.7M) | (633K) | |
(16M) | (19.1M) | (24M) | (30.3M) | (21.4M) | (9.3M) | (7.3M) | (18.3M) | (6.1M) | (19.9M) | (23.6M) | (28.4M) | (21.1M) | (14.6M) | (11.5M) | (7.9M) | (8.9M) | (7.1M) | (6.7M) | (1.3M) | |
-28.3M | -31.5M | -37.9M | -42M | -25.3M | -17M | -20M | -31.6M | -15.7M | -16M | -34.2M | -36.6M | -33.8M | -21.2M | -20.8M | -16.6M | -17.5M | -14.6M | -11.4M | -2.4M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (118K) | (266K) | (462K) | (3.5M) | (760K) | (1.1M) | (807K) | (33K) | (0.0) | (5K) | -5K | (0.0) | (0.0) | (0.0) | |
1.4M | 632K | 525K | 317K | 6K | 26K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3M | (0.0) | (0.0) | (0.0) | (170K) | (37K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
1.4M | 632K | 529K | 649K | 4.4M | 208K | 668K | 2.5M | -7.8M | 5.1M | -4.4M | 13.6M | -41.8M | -13.2M | 9.3M | 4.6M | -867K | 180K | 448K | 0.0 | |
-26.9M | -30.9M | -37.3M | -41.3M | -20.9M | -16.8M | -19.4M | -29M | -23.5M | -17.7M | -38.6M | -36.6M | -75.6M | -34.4M | -11.5M | -12M | -18.4M | -14.4M | -11M | -2.4M | |
NET INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | -237K | -17K | -81K | -1.4M | (253K) | (243K) | (365K) | -15.4M | (1.1M) | -1.1M | (0.0) | (0.0) | (0.0) | (0.0) | (25K) | (0.0) | |
-26.9M | -30.9M | -37.3M | -41.3M | -20.7M | -16.8M | -19.3M | -27.7M | -23.8M | -23.5M | -63.9M | -36.6M | -76.7M | -35M | -11.5M | -12M | -18.4M | -14.4M | -11M | -2.4M |
SEC Filings
SLS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 11, 2026 | March 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your SLS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.